Zhiyun Health Kuang Ming: Using Zhiyun Medical Brain AI technology to improve 'efficiency and effectiveness”

On November 3, 2023, at the 15th China Pharmaceutical Entrepreneurs, Scientists and Investors Conference, the "AI Diagnosis and Treatment, the Future of Innovative Medical Technology" BT IT Hangzhou Ecological Salon was held. Kuang Ming, the founder, chairman and CEO of Zhiyun Health, was invited to attend and delivered a keynote speech. Kuang Ming shared the business logic of Zhiyun Health in the field of digital chronic disease management, as well as the in-depth application of the self-developed AI platform Zhiyun Medical Brain in real diagnosis and treatment scenarios

Kuang Ming said that Zhiyun Health is the largest digital chronic disease management solution provider in the country. At present, Zhiyun Health's self-developed artificial intelligence solutions can not only improve efficiency, but also achieve considerable commercial benefits. In practical applications, this solution demonstrated excellent comprehensive performance

The following is the content of the speech:

Zhiyun Health is the first chronic disease management stock in China and was listed on the Hong Kong stock market last year. We have always placed a high priority on SaaS software and data. This may be related to my professional experience. As the founder and chairman of the company, I have a slightly special background. I have a cross-industry background. I first studied in the Department of Electronic Engineering at Shanghai Jiao Tong University. My first job was at Intel, making chips and doing data-related work. Later, I joined Johnson & Johnson, and I really entered the medical industry.

Using digital technology to manage chronic diseases

Why did we enter the chronic disease field at that time? From our perspective, the chronic disease management market has huge potential and is an ideal entry point for digitalization. my country's medical and health expenditure in 2020 will be more than 7 trillion yuan, of which more than 4 trillion is related to chronic diseases. Our country is also facing serious population aging, which is an irreversible trend, leading to an increasing incidence of chronic diseases. Chronic disease is a long-term disease, and its treatment period may last for decades. If we can form long-term cooperative relationships with medical institutions and patients with chronic diseases, this is a very good business model.

Zhiyun Health was successfully listed during the capital winter last year. Compared with many digital medical companies, our key difference is that we chose and adhered to the "hospital first" strategy. This is because the entire Chinese medical system is based on public hospitals, and we have no chance to start from scratch. Chronic diseases are also a type of disease, in which doctors play an important role in prevention and treatment. Adhering to the "hospital first" strategy, Zhiyun Health has the opportunity to gather a large number of high-quality doctor resources to support the accumulation of the entire basic business

Currently, we have commercial access to nearly 10,000 hospitals, and nearly 2,700 hospitals have installed Zhiyun Yihui SaaS system. A complete set of hospital cooperation logic has been formed. The first step is to reach out to the hospital’s business. The second step is to deploy the SaaS software in the hospital and connect various in-hospital equipment. The final step is commercialization. This is a mature and complete style of play. At present, Zhiyun Health has reached strategic cooperation relationships with more than 80 HIS manufacturers.

The unique business model is an important foundation for Zhiyun Health Medical Brain and Database. To put it simply, our business model is divided into two scenarios: inside the hospital and outside the hospital. The treatment scenarios for chronic diseases are either inside the hospital or outside the hospital. To this end, we developed two different SaaS software, one installed inside the hospital - Zhiyun Medical SaaS, and the other installed in the pharmacy store - Zhiyun Consultation SaaS.

Currently, nearly 2,700 hospitals have installed the Zhiyun Yihui SaaS system, of which tertiary hospitals account for more than a quarter, totaling 780. Among these hospitals, 39 are among the top 100 hospitals, including Peking Union Medical College Hospital, Beijing Anzhen Hospital, Peking University People's Hospital, and the Second Affiliated Hospital of Zhejiang University School of Medicine, etc.

Zhiyun Yihui SaaS coverage is so high mainly because its important functions are well recognized by hospital users. It can standardize and paperless the chronic disease management process in the hospital. It can assist the HIS system to connect many small devices related to chronic diseases in the hospital. In the past, these traditional small devices were difficult to connect to the Internet, forming data islands. It also supports the free flow of disease data related to chronic disease patients between different medical institutions to meet referral and consultation needs.

Zhiyun Consultation SaaS currently has more than 200,000 installed pharmacies, accounting for about one-third of the total number of pharmacies in the country. This number is still growing rapidly. About 20% of them are top 100 chain pharmacies, including Yifeng, Big brands such as Laobin. Zhiyun Consultation SaaS charges fees for pharmacies. It mainly solves the problems of medical diagnosis and prescription writing in stores for people with chronic diseases, takes over outflow prescriptions from hospitals, and can also help pharmacies with online and offline member management.

Based on the huge group of pharmacies using Zhiyun Consultation SaaS, massive amounts of diagnosis and prescription data will be generated every day. Zhiyun Health will conduct data insights and compliant utilization. This is of great value to us.

Achieve double improvement in efficiency and benefits

Zhiyun Health Medical Brain is our AI platform, and its technical capabilities are constantly iteratively upgraded. Let me introduce to you how Zhiyun Medical Brain can be applied to more application scenarios and improve operational efficiency.

The structure of Zhiyun Medical Brain is mainly divided into three layers. The bottom layer is a large medical database. The main difference between this database and other databases is the quality and quantity of data sources. It mainly comes from two parts - medical professional data within the hospital and diagnosis and treatment data on the Internet hospital platform generated by serving pharmacies. Both of them support Zhiyun Medical Brain. Primary data sources. Of course, this part of the data is all compliant and has undergone strict desensitization, allowing for more clinical analysis and clinical research. In terms of prescription volume, Zhiyun Health has become China's largest online medical service provider, providing 170 million online consultations to end users in 2022.

The upper layer of the middle layer architecture is data processing, including data aggregation, cleaning, standardization and structuring

On the next level, there are two large medical models - ClouD GPT and ClouD DTx, which are respectively used in AI-assisted diagnosis and treatment, AI-assisted drug and device research, and real-world research.

Zhiyun Medical Brain provides powerful artificial intelligence capabilities for Zhiyun Medical Exchange SaaS and Zhiyun Consultation SaaS in specific application scenarios

Zhiyun Yihui SaaS system can recommend similar cases to doctors, assist in diagnosis and treatment, realize doctor education, and optimize doctors’ diagnosis and treatment plans.

Zhiyun Consultation SaaS system can provide doctors with scientific medication suggestions to ensure medication safety. For follow-up consultations for patients with chronic diseases, the system can judge the rationality of the consultation based on the patient's chief complaint and disease, and exclude unsuitable patients. During the consultation process, artificial intelligence provides doctors with more scientific and accurate treatment plan suggestions through the traffic light mechanism. After the treatment plan is given, the system will review the treatment plan provided by the doctor again and intercept unreasonable plans in a timely manner. This system provides guarantee for a large number of diagnosis and treatment services on the Zhiyun Health Internet Hospital Platform, greatly improving the platform’s diagnosis and treatment efficiency, quality and safety

In addition, ClouD DTx is based on our big data platform, and its main application directions are auxiliary drug device research and development and real-world research. For example, this year we published an article with an impact factor of more than 12 points, which deeply analyzed the online medication data of more than 1 million patients with high blood pressure and comorbid diseases, revealing the different age, gender, region and different comorbidities of hypertensive patients. The regularity and changing trend of clinical prescription behavior, and a real-world comparative analysis of the standardized specifications and operational implementation of hypertension drug treatment. The results of this study have far-reaching guiding significance for the management of hypertension

This may not seem very complicated, but in fact it is not easy to publish a 12-point article using big data, especially for millions of samples. If traditional scientific research centers were to do the same thing, I don’t know how much money and time it would cost.

We once conducted a real-world study of hypertension in more than 10 million people. The logic of this study is the same. Without a data platform like ClouD DTx, it would be impossible to discover research opportunities like this because the data volume is simply too large to be realized. But our ClouD DTx platform can conduct such big data research at low cost and with high efficiency

Finally, according to the financial data, our company has basically formed a positive cycle. In recent years, we have maintained a compound growth rate of approximately 80%. In the first half of this year, our revenue reached 1.8 billion, and we achieved a substantial reduction in losses, and we are expected to turn losses into profits soon. This makes us more confident that our artificial intelligence solutions can not only improve efficiency, but also ultimately bring considerable business benefits, because they have demonstrated excellent comprehensive performance in practical applications

The above is the detailed content of Zhiyun Health Kuang Ming: Using Zhiyun Medical Brain AI technology to improve 'efficiency and effectiveness”. For more information, please follow other related articles on the PHP Chinese website!